Latest Investor Relations News

The A2 Milk Company has announced its first-ever interim dividend of NZD 0.085 per share, signaling confidence in its financial position and commitment to shareholders.

Contact Energy Limited has announced a fully unfranked dividend of NZD 0.1847 per share, combining ordinary and supplementary components, payable in March 2025.

Citigroup Global Markets Australia has announced a fully franked AUD 0.30 dividend for its ORG CitiFirst Instalments, with key dates set for early March 2025.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.

BSA Limited has temporarily paused trading of its securities, signaling potential significant developments. Investors await further details to understand the implications.

Mirvac Group reports a 2% revenue increase and a remarkable 100% rise in profit attributable to stapled securityholders for H1 2024, even as operating profit after tax declines by 6%.

Cochlear Limited has announced a fully franked dividend of AUD 2.15 per share for the six months ending December 2024, payable in multiple currencies on April 14, 2025.

Cochlear Limited has reported a robust half-year performance with a 7% increase in underlying net profit and an 8% rise in interim dividends, driven by strong sales in cochlear and acoustic implants despite a decline in services revenue.

Evolution Mining Limited has announced a fully franked ordinary dividend of AUD 0.07 per share for the half-year ending December 2024, accompanied by a Dividend Reinvestment Plan offering a 5% discount.

Bravura Solutions Limited has announced an ordinary and special dividend totaling AUD 0.1052 per share for the financial year ending December 2024, signaling steady shareholder returns despite an unfranked payout.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.25 per share for the six months ending December 2024, signaling continued shareholder returns without the need for external approvals.

Pro Medicus Limited delivered a robust half-year performance ending December 2024, with after-tax profits soaring 42.7% to $51.74 million and revenues climbing 31.1% to $97.2 million, driven by significant contract wins in North America and sustained growth in Australia.